PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
19288105-1	2009	PURPOSE: Deficiency of dihydropyrimidine dehydrogenase (DPD) has been associated with severe fluoropyrimidines (FP) toxicity.	fp	112-114	dihydropyrimidine dehydrogenase	Homo sapiens	56-59	
21344302-1	2011	PURPOSE: Eniluracil (EU) is a potent dihydropyrimidine (DPD) inhibitor, which improves the oral bio-availability of 5-fluorouracil (5-FU) and may overcome fluoropyrimidine (FP) resistance in hepatocellular carcinoma (HCC).	fp	173-175	dihydropyrimidine dehydrogenase	Homo sapiens	56-59	
32423482-1	2020	BACKGROUND: Dihydropyrimidine dehydrogenase (DPD) status is an indicator of a marked risk for toxicity following fluoropyrimidine (FP)-based chemotherapy.	fp	131-133	dihydropyrimidine dehydrogenase	Homo sapiens	12-43	
32423482-1	2020	BACKGROUND: Dihydropyrimidine dehydrogenase (DPD) status is an indicator of a marked risk for toxicity following fluoropyrimidine (FP)-based chemotherapy.	fp	131-133	dihydropyrimidine dehydrogenase	Homo sapiens	45-48	
30361102-1	2018	BACKGROUND: Prospective DPYD genotyping prevents severe fluoropyrimidine (FP)-induced toxicity by decreasing dosages in DPYD variant allele carriers.	fp	74-76	dihydropyrimidine dehydrogenase	Homo sapiens	24-28	
30361102-1	2018	BACKGROUND: Prospective DPYD genotyping prevents severe fluoropyrimidine (FP)-induced toxicity by decreasing dosages in DPYD variant allele carriers.	fp	74-76	dihydropyrimidine dehydrogenase	Homo sapiens	120-124	
34780066-1	2022	AIM: Cancer patients with reduced dihydropyrimidine dehydrogenase (DPD) activity are at increased risk of severe fluoropyrimidine (FP)-related adverse events (AE).	fp	131-133	dihydropyrimidine dehydrogenase	Homo sapiens	34-65	
34780066-1	2022	AIM: Cancer patients with reduced dihydropyrimidine dehydrogenase (DPD) activity are at increased risk of severe fluoropyrimidine (FP)-related adverse events (AE).	fp	131-133	dihydropyrimidine dehydrogenase	Homo sapiens	67-70	
35239419-1	2022	PURPOSE: Patients who carry reduced-activity DPYD polymorphisms have increased fluoropyrimidine (FP) toxicity risk.	fp	97-99	dihydropyrimidine dehydrogenase	Homo sapiens	45-49	
32899374-1	2020	Fluoropyrimidines (FP) are mainly metabolised by dihydropyrimidine dehydrogenase (DPD), encoded by the DPYD gene.	fp	19-21	dihydropyrimidine dehydrogenase	Homo sapiens	49-80	
32899374-1	2020	Fluoropyrimidines (FP) are mainly metabolised by dihydropyrimidine dehydrogenase (DPD), encoded by the DPYD gene.	fp	19-21	dihydropyrimidine dehydrogenase	Homo sapiens	82-85	
32899374-1	2020	Fluoropyrimidines (FP) are mainly metabolised by dihydropyrimidine dehydrogenase (DPD), encoded by the DPYD gene.	fp	19-21	dihydropyrimidine dehydrogenase	Homo sapiens	103-107	
32619063-1	2020	Cancer treatment with a fluoropyrimidine (FP) is often accompanied by severe toxicity that may be dependent on the activity of catalytic enzymes encoded by the DPYD, DPYS, and UPB1 genes.	fp	42-44	dihydropyrimidine dehydrogenase	Homo sapiens	160-164